State of New Jersey Common Pension Fund D Has $2.67 Million Holdings in TG Therapeutics, Inc. $TGTX

State of New Jersey Common Pension Fund D increased its position in shares of TG Therapeutics, Inc. (NASDAQ:TGTX) by 34.4% during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 73,933 shares of the biopharmaceutical company’s stock after acquiring an additional 18,926 shares during the period. State of New Jersey Common Pension Fund D’s holdings in TG Therapeutics were worth $2,671,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. PNC Financial Services Group Inc. boosted its stake in shares of TG Therapeutics by 14.2% during the third quarter. PNC Financial Services Group Inc. now owns 11,076 shares of the biopharmaceutical company’s stock valued at $400,000 after purchasing an additional 1,380 shares in the last quarter. Public Sector Pension Investment Board raised its holdings in TG Therapeutics by 14.5% in the 3rd quarter. Public Sector Pension Investment Board now owns 529,271 shares of the biopharmaceutical company’s stock valued at $19,120,000 after buying an additional 66,911 shares during the last quarter. Prospera Financial Services Inc boosted its position in TG Therapeutics by 2.2% during the 3rd quarter. Prospera Financial Services Inc now owns 30,723 shares of the biopharmaceutical company’s stock worth $1,110,000 after buying an additional 648 shares during the period. Profund Advisors LLC grew its holdings in TG Therapeutics by 13.1% during the 3rd quarter. Profund Advisors LLC now owns 50,245 shares of the biopharmaceutical company’s stock worth $1,815,000 after acquiring an additional 5,803 shares during the last quarter. Finally, Smartleaf Asset Management LLC increased its position in TG Therapeutics by 21.0% in the 3rd quarter. Smartleaf Asset Management LLC now owns 2,693 shares of the biopharmaceutical company’s stock valued at $99,000 after acquiring an additional 467 shares during the period. Institutional investors and hedge funds own 58.58% of the company’s stock.

TG Therapeutics Trading Up 0.2%

Shares of TGTX stock opened at $29.53 on Friday. TG Therapeutics, Inc. has a fifty-two week low of $25.28 and a fifty-two week high of $46.48. The company has a debt-to-equity ratio of 0.40, a quick ratio of 2.89 and a current ratio of 3.82. The stock has a 50 day simple moving average of $29.90 and a two-hundred day simple moving average of $31.34. The company has a market cap of $4.69 billion, a P/E ratio of 10.62 and a beta of 1.85.

Analysts Set New Price Targets

A number of equities analysts have recently commented on TGTX shares. B. Riley Financial upgraded shares of TG Therapeutics to a “strong-buy” rating in a report on Tuesday, November 4th. JPMorgan Chase & Co. lowered their target price on TG Therapeutics from $49.00 to $46.00 and set an “overweight” rating for the company in a research report on Monday, February 2nd. The Goldman Sachs Group lifted their target price on TG Therapeutics from $37.00 to $39.00 and gave the stock a “neutral” rating in a report on Thursday, January 15th. Weiss Ratings reissued a “hold (c+)” rating on shares of TG Therapeutics in a research note on Monday, December 29th. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of TG Therapeutics in a research report on Wednesday, January 14th. One investment analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and two have given a Hold rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $50.00.

Insider Activity

In related news, Director Yann Echelard sold 5,000 shares of the stock in a transaction on Monday, November 24th. The shares were sold at an average price of $32.57, for a total transaction of $162,850.00. Following the transaction, the director directly owned 223,816 shares of the company’s stock, valued at $7,289,687.12. This represents a 2.19% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 10.64% of the stock is owned by insiders.

TG Therapeutics Profile

TG Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in New York City that specializes in developing targeted therapies for hematological malignancies and autoimmune diseases. The company’s research strategy focuses on the modulation of B-cell biology through novel antibody and small‐molecule agents. Since its founding in 2003, TG Therapeutics has built a diversified portfolio aimed at addressing unmet medical needs in oncology and immunology.

In December 2022, TG Therapeutics achieved its first commercial milestone when ublituximab-xiiy (marketed as Briumvi® in collaboration with Biogen) received U.S.